Synthesis, Structure Elucidation, Antibacterial Activities, and Synergistic Effects of Novel Juglone and Naphthazarin Derivatives Against Clinical Methicillin-Resistant Staphylococcus aureus Strains

Infections caused by drug-resistant bacteria are a serious threat to human and global public health. Moreover, in recent years, very few antibiotics have been discovered and developed by pharmaceutical companies. Therefore, there is an urgent need to discover and develop new antibacterial agents to combat multidrug-resistant bacteria. In this study, two novel series of juglone/naphthazarin derivatives (43 compounds) were synthesized and evaluated for their antibacterial properties against various clinical and reference Gram-positive MSSA, clinical Gram-positive MRSA, and clinical and reference Gram-negative bacteria E. coli and P. aeruginosa. These strains are of clinical importance because they belong to ESKAPE pathogens. Compounds 3al, 5ag, and 3bg showed promising activity against clinical and reference MSSA (MIC: 1–8 µg/ml) and good efficacy against clinical MRSA (MIC: 2–8 µg/ml) strains. 5am and 3bm demonstrated better activity on both MSSA (MIC: 0.5 µg/ml) and MRSA (MIC: 2 µg/ml) strains. Their MICs were similar to those of cloxacillin against clinical MRSA strains. The synergistic effects of active compounds 3al, 5ag, 5am, 3bg, and 3bm were evaluated with reference antibiotics, and it was found that the antibiotic combination with 3bm efficiently enhanced the antimicrobial activity. Compound 3bm was found to restore the sensitivity of clinical MRSA to cloxacillin and enhanced the antibacterial activity of vancomycin when they were added together. In the presence of 3bm, the MIC values of vancomycin and cloxacillin were lowered up to 1/16th of the original MIC with an FIC index of 0.313. Moreover, compounds 3al, 5ag, 5am, 3bg, and 3bm did not present hemolytic activity on sheep red blood cells. In silico prediction of ADME profile parameter results for 3bm is promising and encouraging for further development.


INTRODUCTION
The introduction of antibiotics into clinical use was the major therapeutic advance of the 20th century (Trémolières, 2010). Antibiotics are the main treatment for bacterial infections and made possible many modern medical healthcare such as for people with cancers or organ transplants. However, extensive use and misuse of antibiotics in humans, animals, and plants combined with a diminished lack of interest by the pharmaceutical industry has led to the rapid rise of antimicrobial resistance (AMR) (Jabes, 2011;Stanton, 2013).
Unfortunately, the development of new drugs in clinical research is low; only two new classes of antibiotics: oxazolidinones (2000) and lipopeptides (2003) were introduced during the last decade (WHO Antibiotic resistance: No action today, no cure tomorrow, 2011). In addition, accumulation of antibiotics in the environment may be the result of dissemination of resistant bacteria with antibiotic resistance genes (Tan and Shuai, 2015). AMR infections are recognized by the World Health Organization (WHO) as a global concern for public health (WHO | Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug resistant bacterial infections, including tuberculosis, 2017). Bacterial resistance is responsible for approximately 700,000 death annually and will likely increase the death rate in the next few years, and it will become the first leading cause of mortality in the world in 2050 (de Kraker et al., 2016;O'Neil, 2016). Increasing resistance to conventional drugs by strains such as methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa (P. aeruginosa), and Escherichia coli (E. coli) is pushing us to find new classes of antibiotics to circumvent multidrug-resistant infections. These pathogens belonging to the ESKAPE group are a priority for the development of new compounds with antibacterial properties (Mulani et al., 2019).
The development of novel and structurally diverse compounds with potential antimicrobial properties is highly needed. Naphthoquinones are an important class of quinones found in many synthetic and natural products and are known to possess various functions and biological applications (Pinho et al., 2012). Indeed, natural or synthetic 1,4-naphthoquinone derivatives exhibited strong action as antimalarial, anticancer, antiinflammatory, antifungal, and antibacterial agents (Fernando and Vitor, 2016;Aminin and Polonik, 2020). Naphthoquinones exert their biological properties via several mechanisms such as the production of reactive oxygen species (ROS). The 1,4-naphthoquinone moiety is present in many alkaloids such as lawsone, plumbagin, juglone, and naphthazarin.
Juglone (5-hydroxy-1,4-naphthoquinone, Figure 1a) is present in Juglandaceae species, and naphthazarin (5,8-dihydroxy-1,4-naphthoquinone, Figure 1b) is derived from the tissues of Boraginaceae, Droseraceae, and Nepenthaceae families (Papageorgiou et al., 1999;Thakur, 2011;Devi et al., 2016). Previously, natural or synthetic juglone/ naphthazarin derivatives exhibited antibacterial activity on various bacterial strains (minimal inhibitory concentration (MIC) values ranging from 0.78 to 100 μg/ml) (Clark et al., 1990;Shen et al., 2002;Jeon et al., 2009;Yakubovskaya et al., 2009;Sánchez-Calvo et al., 2016;Wang et al., 2016). However, determination of the MIC following a broth dilution assay on both reference and clinical bacterial strains of S. aureus and E. coli isolated from patients in a university hospital is an important part in this study. It is for the first time that 1,4-naphthoquinone derivatives are evaluated on clinical bacterial strains. Furthermore, evaluation of the adjuvant effect of the synthesized molecules on clinical resistant bacteria revealed potential restoration of activity between newly synthesized compounds and reference antibiotics. These evaluations against resistant bacteria, known to cause therapeutic problems in hospitals, are less reported in the literature.
With the aim of seeking further antibacterial active substances, we report the synthesis of two classes of 1,4naphthoquinone derivatives (juglone and naphthazarin derivatives) and the X-ray structural determination of two compounds. The antimicrobial profiles of the compounds against clinical sensitive and clinical resistant Gram-positive and Gram-negative bacteria are evaluated. Additionally, their synergistic effects in combination with two conventional antibiotics cloxacillin and vancomycin were investigated. Finally, we also determined the in vitro hemolytic activity of the most active compounds and the in silico ADME parameters of all compounds.

Chemistry
The synthesis of juglone and naphthazarin derivatives 3, 4, and 5 was accomplished using Minisci-type direct C-H alkylation, as illustrated in Scheme 1 (Sutherland et al., 2018). Commercially, juglone (1a) and naphthazarin (1b) react with 11 commercially available carboxylic acids (2) in the presence of ammonium persulfate to afford 1, 2, or 3 different products with one or two alkylated chains in different positions (3, 4, and 5) in low to moderate yields ( Table 1). Starting from juglone (1a), two monoalkylated juglone derivatives (3 and 5) and a dialkylated juglone derivative (4) were obtained in most cases. Starting from naphthazarin (1b), one monoalkylated naphthazarin derivative (3) and the dialkylated naphthazarin derivative (4) were obtained in most cases. Indeed, for some carboxylic acids, we observed the formation of only one monoalkylated naphthazarin derivative (3bc, 3bd, 3be, 3bg, 3bh, and 3bm), and for other carboxylic acids, the dialkylated naphthazarin derivatives (4bf and 4bl) were the sole products. The low yields of each compound (3, 4, and 5) obtained during this reaction are due, on the one hand, to the formation of secondary products (not isolated) and, on the other hand, to the tricky purification of the products ( Table 1). Although Sutherland et al. (2018) described the synthesis of 3ac, 4ac, and 5ac with good yields, we did not obtain the same yields. In addition to their studies, we were able to characterize each regioisomer (3 or 5) using NMR spectroscopy, in particular heteronuclear multiple bond correlation (HMBC), and X-ray diffraction techniques (see the Supporting Information). The final compounds were fully characterized by 1 H nuclear magnetic resonance (NMR), 13 C NMR, HMBC, and infrared (IR) spectroscopy; high-performance liquid chromatography (HPLC); and high-resolution mass spectrometry (HRMS). The spectroscopic data of the compounds are consistent with the assigned structures (see the Experimental Section and the Supporting Information).

X-Ray Crystallographic Analysis
Two X-ray crystal structures were used to establish the authenticity of the basic structures. This analysis was performed on compounds 5ae and 3bg that were obtained from juglone and naphthazarin, respectively, and X-ray and structure refinement statistics are presented in Table 2.
An orange plate-like crystal of compound 5ae (C 18 H 22 O 3 ) with an approximate dimension of 0.25 × 0.10 × 0.01 mm and a black plate-like specimen of compound 3bg with an approximate dimension of 0.12 × 0.05 × 0.03 mm were used for X-ray diffraction. Compound 5ae was crystallized in the monoclinic crystal system using the space group P 2 1 , and 3bg was crystallized in the monoclinic crystal system using the space group C 2/c. For 5ae, we observed that the structure is completely planar with the n-octyl substituent staying linear in the mesh.

In Vitro Antibacterial Activity
In this work, we studied the antibacterial activity of our series of compounds derived from juglone and naphthazarin. To our knowledge, none of the newly synthesized molecules has been evaluated for their antibacterial properties against sensitive and resistant clinical strains of S. aureus.
Antibiotic Susceptibility Testing Against Reference and Sensitive Clinical Strains of E. coli, S. aureus, and P. aeruginosa The newly synthesized juglone and naphthazarin derivatives 3, 4, and 5 were subjected to antibiotic susceptibility testing against reference and sensitive clinical strains of E. coli: ATCC 25922 and NEC-S1; S. aureus: ATCC 29213 and NSASM-1; and P. aeruginosa: PAO1. MICs against Gram-positive and Gramnegative strains were determined by using the broth microdilution assay. These strains are known to be sensitive to reference antibiotics: Cefotaxime is the reference antibiotic to treat sensitive Gram-negative bacteria, and cloxacillin and vancomycin are reference antibiotics to treat sensitive Grampositive strains (The European Committee on Antimicrobial Susceptibility Testing, 2021). These compounds 3, 4, and 5 were then evaluated against different bacterial strains to determine their antibacterial activities ( Table 3).
Compounds 3, 4, and 5 showed a variable antibacterial activity although their structures are similar. We observed a huge difference in terms of activity, varying from an MIC of 0.5 to an MIC superior to 128 µg/ml. The antimicrobial screening results suggested that the synthetized compounds exhibited a selective inhibitory activity against the reference and clinical Gram-positive S. aureus strains.
Concerning the juglone moiety, an interesting difference in antibacterial activity was observed. Only one dialkylated compound 4ac exhibited an activity against methicillinsusceptible Staphylococcus aureus (MSSA) with an MIC of 32 µg/ml, whereas two other monoalkylated products with the same alkyl group showed a lower activity on these two strains with an MIC of, respectively, 128 µg/ml for 3ac and 64 µg/ml for 5ac.
Second, a difference in antibacterial activity between the two monoalkylated regioisomers was observed. When the alkyl group was grafted on C3 (compounds 5), antibacterial activity was better than that in the other monoalkylated regioisomer grafted on C2 (compounds 3). 3am showed an MIC of 128 µg/ml on the reference and clinical MSSA strains, whereas 5am showed an MIC of 0.5 µg/ml on MSSA. The same results were observed for 3ag/5ag, 3ad/5ad, 3ah/5ah, and 3ac/ 5ac. Three exceptions with 3aj/5aj, 3ak/5ak, and 3al/5al were noticed.
Considering naphthazarin derivatives, MIC activities were lower than those for juglone derivatives for most compounds. The only naphthazarin compound that had a better antibacterial activity than juglone was 3bi with an MIC of 4 µg/ml versus 3ai with an MIC of 128 µg/ml on MSSA.
These results are promising in comparison with those described in the literature. Indeed, the in vitro antibacterial activity of juglone ( Figure 1, 1a) against S. aureus was investigated. The authors showed that juglone exhibits activity against MSSA with an MIC of 12.5 µg/ml (Clark et al., 1990). In our studies, we showed that compounds 5am and 3bm showed promising activity against clinical and reference MSSA (MIC: 0.5 µg/ml). The MIC was improved by a 24-fold factor.

Antibiotic Susceptibility Testing Against Resistant Clinical Strains of E. coli and S. aureus
We further evaluated antibacterial activity of compounds against one clinical isolate of methicillin-resistant Staphylococcus aureus (MRSA) and one clinical isolate of extended spectrum betalactamase (ESBL) E. coli. Both strains have been isolated from patients; E. coli is considered as resistant because of the high cefotaxime MIC (breakpoint of 2 μg/ml). This strain is an ESBLproducing bacteria and known to be resistant to most beta-lactam antibiotics. S. aureus is considered as resistant because of the high cloxacillin MIC (breakpoint of 2 μg/ml). The MRSA strain used is mainly resistant to the penicillin family but not to the glycopeptide family like vancomycin (breakpoint of 2 μg/ml) ( Table 4) (Boibessot et al., 2016;Douafer et al., 2019; The European Committee on Antimicrobial Susceptibility Testing, 2021).
The results are summarized in Table 4. Compounds 5ag, 5am, 3bg, and 3bm displayed potent antibacterial activity with an MIC of 2 μg/ml against MRSA. Compound 3al showed antibacterial inhibition with an MIC of 8 μg/ml. Compounds 4ac, 5ac, 5ah, 3aj, 3ak, 5al, and 3bi exhibited moderate inhibition with an MIC varying from 16 to 64 μg/ml. All compounds were found to be inactive against resistant clinical isolates of E. coli.
Our studies showed that the newly synthesized derivatives are not active against E. coli strains, the possible reason being that the compounds do not enter the bacteria because of its outer membrane and lack of access of the compounds, or the resistance mechanism of E. coli strains limiting the number of entryways and expressing less porins on the bacterial outer layer (Pagès et al., 2008).

Structure Activity Relationship Study
From our previous observation, some conclusions can be realized on sensitive and resistant bacterial strains. First, naphthazarin derivatives were found to be less potent than juglones. However, three exceptions were observed: 3bg, 3bm, and 3bi with MICs between 0.5 and 16 µg/ml ( Figure 4A). Then the presence of a long aliphatic alkyl chain seemed unfavorable for the antibacterial activity. Compounds grafted with n-hexyl chains had a low activity (from 32 to 128 µg/ml for 3ac-5ac) except for 5ad. Moreover, with n-octyl and n-nonyl moieties, no antibacterial activity was observed for compounds 3ae-5af. The same point was previously observed in the literature with naphthoquinones: The longer the carbon chain is, the higher the lipophilicity is and the lower the antimicrobial activity is (Sánchez-Calvo et al., 2016). Here, when the product is dialkylated, the activity is very low and  only 4ac showed antibacterial activity ( Figure 4B). Considering the influence of the position of the grafted chain, we observed that when the alkyl chain was on C3 (compounds 5), antibacterial activity was way higher than when C2 was substituted (compounds 3, Figure 4C). Finally, the nature of the alkyl group was investigated. Best results were obtained when the alkyl group was ramified and contained between five and seven carbon atoms, especially with cyclohexyl and heptan-4-yl ( Figure 4D).

Synergistic Effect of the Synthesized Compounds With Cloxacillin and Vancomycin by Fractional Inhibitory Concentration Index (FICI) Measurements
One strategy to solve the problem of ABR is to use an antibiotic adjuvant in combination with an antibiotic which will slow down the evolution of the bacteria's resistance profile (Kim et al., 2014;Wright, 2016). Measurement of the synergy of the newly synthesized derivatives with existing antibiotics is an important strategy to fight drug-resistant bacteria.
These results showed the absence of synergy for compounds 5am and 3bg with vancomycin and for compound 5am with cloxacillin (FIC ≥ 1). An additivity phenomenon was observed for compounds 3al and 5ag with vancomycin and for compounds 5ag and 3bg with cloxacillin (0.5 < FIC < 1). Finally, compound 3bm showed synergy with both vancomycin and cloxacillin with FIC 0.313 ( Table 5). For 3bm, this is expressed by a fold potentiation of 16 for vancomycin (0.5-0.03 µg/ml) and cloxacillin (2-0.125 µg/ml). This potentiation is visible on following heat maps. The potentiation is not only due to the antibacterial properties of 3bm as proven by our FICI measurements ( Figure 6). We also observed the restoration of vancomycin and cloxacillin activities on resistant strains of S. aureus. The MIC of cloxacillin and vancomycin on MSSA is 0.25 µg/ml, and the MICs of cloxacillin and vancomycin on MRSA are, respectively, 0.06 µg/ml and 0.03 µg/ml in the presence of 0.25 µg/ml of 3bm. This observation means that in the presence of 0.25 µg/ml of 3bm, a concentration of antibiotics 16 times lower is amply enough to inhibit bacterial growth.
Finally, 3bm is the only derivative to possess a synergistic effect with known antibiotics and can be, therefore, considered as an interesting compound for further studies (Figure 7).

Hemolysis
The erythrocytes of mammals represent an excellent model to perform an in vitro evaluation of the cytotoxicity of molecules. Many published research studies have documented the possibility of using the resistance of mammalian red blood cell (RBC) membranes as a method of toxicity evaluation, by exposing sheep RBCs, using a standard protocol (material and methods), to different

In silico ADME Study
Identifying and predicting the pharmacokinetics (PKs) of molecules is an important step in drug discovery. The PK profile is very often requested in medicinal chemistry projects and increasingly at an early stage of research projects. Modeling approaches are among the tools available to meet this data need. PK is one of the main reasons for stopping the development of a drug candidate; to avoid this problem, different in silico models have been recently developed. However, in practice in vitro tests seem to be essential to confirm the predictions. In this study, we used SwissADME, which is freely accessible and was originally developed to study the impact of orally active compounds on gastrointestinal absorption and bioavailability and delineated the relationship between pharmacokinetic and physicochemical parameters (Daina et al., 2017). SwissADME, as its name suggests, allowed us to have access to preclinical data, especially in vitro data, on absorption, distribution, metabolism, and excretion (ADME). Table 6 summarizes the results obtained from most active juglone and naphthazarin derivatives with MIC ≤ 32 μg/ml and presents some predicted physicochemical and pharmacokinetic parameters. Particular attention has been given to pharmacokinetic properties, for example, gastrointestinal absorption (GI), blood-brain barrier (BBB) permeability, and cytochrome P450 (CYP) enzyme inhibitions. All of the compounds of interest showed good compatibility with Lipinski's "rule of five" (Lipinski et al., 2012). The predicted values of cLogP are in the ideal range of LogP to be presented in the context of compound development. High gastrointestinal absorption (GI) is shown as well as the metabolism by the major drug-metabolizing CYP isoforms expressed in the liver (CYP1A2, CYP2C19, CY2C9, CYP2D6, and CYP3A4). Moreover, it is also important to estimate the fraction of drugs metabolized by these major CYP isoforms by performing in vitro ADME assays. Another important pharmacokinetic parameter blood-brain barrier (BBB) permeability was predicted in silico, and BBB was shown to be permeable to all evaluated molecules. This may be due to the weight of the juglone compounds: their molecular weight does not exceed 450 Da. Lipophilicity has a positive correlation with the ability to cross BBB, usually LogP for neutral compounds, with a minimal hydrophobicity (LogP > 5), which is the case of our compounds (Fong, 2015). And eventually orally administered juglone does not lead to an increase in the activity of Pgp, which is the most important member of active drug transporters, leading to multidrug resistance.

EXPERIMENTAL SECTION Chemistry
All reagents were purchased from Aldrich Chemical Co. and used without any purification. NMR spectra were recorded with a Clinical MRSA strain penicillinase producer resistant to the penicillin family and susceptible to vancomycin. b Clinical ESBL E. coli strain resistant to most beta-lactam antibiotics.
Frontiers in Chemistry | www.frontiersin.org November 2021 | Volume 9 | Article 773981 8 a Bruker Avance 300 spectrometer (300 and 75 MHz for 1 H and 13 C NMR, respectively). Chemical shifts (δ) and coupling constants (J) are given in ppm and Hz, respectively, using residual solvent signals as reference for 1 H and 13 C. The following abbreviations are used: s singlet, d doublet, t triplet, q quartet, quint quintuplet, br s broad signal, dd double doublet, dt double of triplet, and m multiplet. Highresolution mass spectra (HRMS) were obtained by electrospray ionization using a TOF analyzer platform. IR spectra were obtained using a JASCO FT-IR 410 instrument on a thin film on NaCl disc as stated; only structurally important peaks (υ) are presented in cm −1 . Reactions were monitored with Merck Kieselgel 60F254 precoated aluminum silica gel plates (0.25 mm thickness). Melting points were determined on a Stuart scientific SMP10 apparatus and are uncorrected. Flash chromatography was performed on a Grace Reveleris X2 apparatus using a 40-μm packed silica cartridge. Flash chromatography experiments were carried out on silica gel premium R f : grade (40-63 μm) or were performed on a Grace Reveleris X2 using a 40-μm packed silica cartridge. HPLC analyses were obtained on a Waters Alliance 2795 system using the following conditions: a Thermo Hypersil C18 column (3 μm, 50 mm L × 2.1 mm ID), 20°C column temperature, 0.2 ml/min flow rate, photodiode array detection (210-400 nm), and mobile phase consistent of a gradient of water and acetonitrile (each containing 0.1% trifluoroacetic acid). The purity of all synthetic compounds was determined by HPLC analysis and was > 95%.

X-Ray Crystallographic Studies
The X-ray single crystal data of 5ae and 3bg were collected with monochromated Mo-Kα radiation (0.71073 Å) on a Bruker Apex3 CCD diffractometer. Intensity data were collected at 123 K using the θ-scan method. Data reduction of each compound was carried out using Bruker SAINT software. Multi-scan absorption correction was applied to all intensity data using the SADABS 2016/2 program (Krause et al., 2015). The structures were solved by a combination of direct methods with SHELXT-2014/5 and refined with full-matrix least-squares based on F 2 using SHELXL 2018/3 (Sheldrick, 2015). The hydrogen atoms were treated by a mixture of independent and constrained refinement. Molecular and the crystal packing diagrams were drawn with Mercury software. Bruker SHELXTL was used to prepare material for publication and realize molecular graphics. All of the crystal data are described in supporting information. The crystal structures were deposited at the Cambridge Crystallographic Database Centre (CCDC) and given the numbers CCDC 2083158 and 2083159.

Antibacterial Assays
All used bacteria were donated by the CHU of Nîmes and were cultivated in Mueller-Hinton broth (MHB) in this study. For plating bacteria, 1.7% agar was added to the respective broth. Briefly, six bacterial strains were cultivated. One reference Grampositive strain: Staphylococcus aureus (ATCC 29213), and two clinical Gram-positive strains isolated from a patient and given by the Nîmes University Hospital: sensitive Staphylococcus aureus, NSASM-1, and resistant Staphylococcus aureus, NSARM-1, were used. NSASM-1 is a sensitive strain to reference antibiotics cloxacillin or vancomycin, and NSARM-1 is a S. aureus strain and is considered as resistant because of the high cloxacillin MIC (breakpoint of 2 μg/ml); hence, this strain is resistant to the penicillin family but not to the glycopeptide family like vancomycin (breakpoint of 2 μg/ml). Two reference Gramnegative strains: Escherichia coli (ATCC 25922) and Pseudomonas aeruginosa (PAO1) and two clinical Gramnegative strains isolated from a patient and given by the Nîmes University Hospital: sensitive Escherichia coli, NEC-S1, and resistant Escherichia coli, NEC-R3 (extended spectrum beta lactamase (ESBL)), were used. NEC-S1 is the sensitive E. coli strain to the reference antibiotics cefotaxime. NEC-R3 is the E. coli strain considered as resistant because of the high cefotaxime MIC (breakpoint of 2 μg/ml). This strain is an ESBL-producing bacteria and known to be resistant to most beta-lactam antibiotics. All bacteria were routinely grown at 37°C under agitation at 200 rpm. 5.12 mg of all compounds were solubilized in a 15-ml flask with 2 ml of DMSO and 8 ml of Mueller-Hinton broth (C m 512 µg/ml). Then serial dilutions of 1:2 were realized from this solution (0.5 < C m < 256 µg/ml). The final concentration in the wells was 0.25-128 µg/ml. The MIC of the tested compounds was determined by using the 2-fold serial broth (MHB medium) dilution method in 96-well (U-base TPP) plates according to the European Committee of Antimicrobial Susceptibility Testing (EUCAST) guidelines (The European Committee on Antimicrobial Susceptibility Testing, 2021). Briefly, each well contained a cell density of (3−7) × 10 5 CFU/ml and compound concentrations ranging from 0.5 to 128 μg/ml. After incubation for 20 h at 37°C, MICs were read as the lowest concentration of the compound that completely inhibited growth.

Determination of the Fractional Inhibitory Concentration Index
The fractional inhibitory index of most active compounds (5ag, 3al, 5am, 3bg, and 3bm) was determined as follows. To test the effect of adjuvants on bacterial resistance, a clinical bacterial strain was selected: Staphylococcus aureus isolate NSARM-1. The MICs of a panel of antibiotics including cloxacillin (CXL) and vancomycin (VCM) were determined by the broth microdilution method as described by EUCAST (The European Committee on Antimicrobial Susceptibility Testing, 2021). The bacterial inoculate was set at 5.10 5 CFU/ml. The 96-well plates were used to allow concentrations of each antimicrobial to be varied along different axes (from 0.015 to 32 µg/ml for synthesized compounds and from 0.015 to 4 µg/ml for antibiotics), thus ensuring that each well of the plate represents a different combination. The synergistic effect was calculated with the fractional inhibitory concentration index (FICI), following the equation described below ( Figure 5). Synergistic action can be considered when the FICI is below 0.5; the additivity effect when the FICI is between 0.5 and 1; indifference when the FICI is between 1 and 4; and antagonism when the FICI is below 4. All the plates were realized in duplicates. Absorption at 600 nm of each well was read with an EPOCH2C microplate reader, BioTek Instrument, Inc. (Highland Park, Winooski, VT.) with Gen5 software (version 2.06.10). The negative control average was considered as 100% inhibition, and the positive control average was considered as 0% inhibition. Heat maps were realized with RStudio software (see Supplementary  Information).

Hemolysis Assay
Hemolysis assay on juglone derivatives was performed according to previous reports with minor modifications (Kent et al., 1988;Mesdaghinia et al., 2019). After washing and resuspending in phosphate-buffered saline (PBS), 250 µl of 5% (v/v) of sheep erythrocyte solution was added to Eppendorf tubes, and then the same volume of compound was added at various concentrations (3al, 5ag, 5am, 3bg, and 3bm). Each hemolysis reaction contained 5% (v/v) RBCs, 5% (v/v) DMSO, and a specific concentration of the respective compounds. The samples were incubated for 1 h at 37°C under agitation at 100 rpm. 0.5% Triton X-100 and PBS were used as positive control and negative control, respectively. After incubation, the RBCs were separated from the reaction mixture by centrifugation at 1000 g and 4°C. The experiments were performed in triplicate. Hemolytic activities of the compounds or lack thereof was determined visually.